Jack Nielsen
Partner
management team
ANOKION
Switzerland
Biography
Jack joined Novo A/S in 2001. He is chairman of the Board of Directors of Alios BioPharma Inc., and a member of the Board of Directors of Apollo Endosurgery Inc., Akebia Therapeutics Inc., ProteinSimple, Reata Pharmaceuticals Inc. and Tobira Therapeutics Inc. Previously, he was a board member of MediQuest Therapeutics Inc., NeoMend Inc. and Protein Forest Inc. From 2006-2012, Jack was employed with Novo Ventures (US) Inc. in San Francisco, California as a partner. From 1990-2001, he held various positions in the Novo Nordisk business area which in 2000 became Novozymes A/S. Before joining Novo A/S, Jack spent several years deeply involved in designing the R&D strategy for Novozymes' activities in the cereal food area, resulting in the development and launch of novel recombinant lipase and amylase enzymes. He has also held positions in marketing and technical services in the textile and personal care area, and started his career in the field of large-scale manufacturing of enzymes.
Research Interest
novel recombinant lipase and amylase enzymes
